Kane Biotech Inc. (CVE:KNE – Get Free Report) shares traded down 13% during mid-day trading on Monday . The stock traded as low as C$0.10 and last traded at C$0.10. 235,000 shares were traded during trading, an increase of 90% from the average session volume of 123,822 shares. The stock had previously closed at C$0.12.
Kane Biotech Stock Down 4.8 %
The business has a fifty day simple moving average of C$0.12 and a two-hundred day simple moving average of C$0.13. The company has a market cap of C$13.25 million, a PE ratio of -3.33 and a beta of 0.52. The company has a current ratio of 0.82, a quick ratio of 0.39 and a debt-to-equity ratio of 1,164.24.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Read More
- Five stocks we like better than Kane Biotech
- What is MarketRank™? How to Use it
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- Basic Materials Stocks Investing
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- What is the Euro STOXX 50 Index?
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
